Evidence map›Paper›PMID 33905848›Full record

ArticleAnnals of vascular surgery2021

Dissecting the Management and Outcomes of Thoracic Aortovascular Disease During the COVID-19 Pandemic.

Iain McPherson, Nicholas Chilvers, Kathrin Freystaetter, Ashwin Sivaharan, Mazyar Kanani, Robin Williams, James McCaslin, Sandip Nandhra, Karen Booth

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Annals of vascular surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Iain McPhersonDepartment of Cardiothoracic Surgery, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom. Electronic address: iain.mcpherson@nhs.net.
Nicholas ChilversDepartment of Cardiothoracic Surgery, James Cook University Hospital, Middlesbrough, United Kingdom.
Kathrin FreystaetterDepartment of Cardiothoracic Surgery, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom.
Ashwin SivaharanNorthern Vascular Centre, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom.
Mazyar KananiDepartment of Cardiothoracic Surgery, James Cook University Hospital, Middlesbrough, United Kingdom.
Robin WilliamsNorthern Vascular Centre, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom.
James McCaslinNorthern Vascular Centre, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom.
Sandip NandhraNorthern Vascular Centre, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom.
Karen BoothDepartment of Cardiothoracic Surgery, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom.
Freeman Hospital · GBJames Cook University Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe COVID-19 pandemic has forced the cancellation of planned surgery and led to significant surgical service reductions. Early intervention in aortovascular disease is often critical and cannot be deferred despite these reductions. There is urgent need to evaluate the provision and outcomes of thoracic aortovascular intervention during the peak of the pandemic.

methodsProspective data was collected for patients receiving open and endovascular thoracic aortovascular intervention over two-time points; January-May 2020 and January-May 2019 at three tertiary cardiovascular centres. Baseline demographics, cardiovascular risk and COVID-19 screening results were noted. Primary outcomes were median length of intensive care unit and hospital stay, intra-operative mortality, 30-day mortality, post-operative stroke, and spinal cord injury.

resultsPatients operated in 2020 (41) had significantly higher median EuroSCORE II than 2019 (53) (7.44 vs. 5.86, P = 0.032) and rates of previous cardiac (19.5% vs. 3.8%, P = 0.019), aortic (14.6% vs. 1.9%, P = 0.041), and endovascular (22.0% vs. 3.8%, P = 0.009) intervention. There was an increase in proportion of urgent cases in 2020 (31.7% vs. 18.9%). There were no intra-operative deaths in 2020 and 1 in 2019 (P = 1.00). There were no significant differences (P ≥ 0.05) in 30-day mortality (4.9% vs. 13.2%), median intensive care unit length of stay (72 vs. 70 hr), median hospital length of stay (8 vs. 9 days), post-operative stroke (3 vs. 6), or spinal cord injury (2 vs. 1) between 2020 and 2019 respectively.

conclusionsDespite the increased mortality risk of patients and urgency of cases during COVID-19, complicated by the introduction of cohorting and screening regimens, thoracic aortovascular intervention remained safe with comparable in outcomes to pre-COVID-19.

Indexed as

COVID-19Vascular Surgical ProceduresAgedAged, 80 and overAorta, ThoracicAortic DiseasesCOVID-19 TestingDatabases, FactualEnglandFemaleHospital MortalityHumansLength of StayMaleMiddle AgedPatient Safety

Identifiers

PMID33905848
PMCPMC8124015
OpenAlexW3157794105

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.